Samsung Biologics, a global leader in contract development and manufacturing organization (CDMO) services for the biopharmaceutical industry, has announced that its product carbon footprint (PCF) system has successfully undergone independent validation by Det Norske Veritas (DNV), a globally recognized assurance and risk management provider. This milestone confirms that the company’s methodology for calculating product-level greenhouse gas emissions aligns with internationally accepted environmental standards and reinforces Samsung Biologics’ commitment to transparency, accountability, and sustainability across its operations.
The independent validation verifies that Samsung Biologics’ PCF calculation framework complies with key global benchmarks, including ISO 14067 and PAS 2050. These standards establish internationally recognized principles for quantifying and reporting the carbon footprint of products throughout their lifecycle. By meeting these rigorous requirements, Samsung Biologics demonstrates that its carbon accounting practices are not only technically robust but also consistent with the expectations of regulators, partners, and customers across the global biopharmaceutical value chain.
This achievement reflects years of systematic development and refinement of internal sustainability processes. The company has invested significantly in building a comprehensive methodology capable of capturing emissions data across complex biopharmaceutical manufacturing activities, from raw material sourcing and production to packaging and distribution. Establishing such a framework is particularly challenging in biologics manufacturing, where energy-intensive processes, specialized equipment, and strict regulatory controls create intricate operational environments. The validated PCF system therefore represents both a technical and strategic advancement for Samsung Biologics.
DNV, headquartered in Norway, conducted a detailed and independent assessment of the company’s PCF system. The evaluation examined multiple components of the framework, including data collection procedures, emission factor selection, calculation models, assumptions, and final output reporting. DNV confirmed that the structure and methodology adhere to globally accepted scientific and technical practices, ensuring that the resulting carbon footprint data is credible, traceable, and suitable for external disclosure. Independent assurance of this nature is increasingly important as stakeholders demand verifiable sustainability information rather than self-reported metrics.
Through the implementation of a validated PCF framework, Samsung Biologics aims to improve clarity and comparability in how product-level emissions are communicated throughout the biopharmaceutical ecosystem. Pharmaceutical companies, healthcare providers, regulators, and investors are placing growing emphasis on environmental performance, and consistent carbon accounting methodologies are essential for meaningful evaluation. By aligning its system with global standards, Samsung Biologics enables customers to better understand the environmental impact of their supply chains and to make informed decisions that support corporate climate goals.
John Rim, President and Chief Executive Officer of Samsung Biologics, emphasized the broader significance of the validation. He noted that independent confirmation of the company’s PCF methodology underscores the rigor and transparency of the carbon data shared with clients. According to Rim, the milestone reflects Samsung Biologics’ ongoing commitment to building sustainable operations grounded in recognized global standards while maintaining the reliability and manufacturing excellence expected by partners worldwide. As sustainability considerations increasingly influence procurement strategies and long-term partnerships in the biopharmaceutical sector, Rim highlighted that a credible PCF system can serve as a foundation for deeper collaboration and shared progress toward emissions reduction.
The validation also aligns with wider global trends shaping the life sciences industry. Governments and regulatory bodies across multiple regions are introducing stricter climate disclosure requirements, while pharmaceutical companies are setting ambitious net-zero targets that extend across their value chains. CDMOs such as Samsung Biologics play a crucial role in enabling these ambitions, as outsourced manufacturing contributes significantly to the overall environmental footprint of drug production. By providing independently verified emissions data at the product level, Samsung Biologics positions itself as a strategic sustainability partner capable of supporting customers’ regulatory compliance and environmental commitments.
Beyond carbon accounting, Samsung Biologics has been expanding its broader sustainability initiatives. The company continues to invest in energy efficiency, renewable energy sourcing, waste reduction, and responsible resource management within its large-scale manufacturing campuses. These operational improvements complement the PCF framework by addressing emissions at their source rather than solely measuring them. Together, measurement, transparency, and reduction form the core pillars of an effective climate strategy, and Samsung Biologics’ recent progress suggests an integrated approach rather than isolated environmental programs.
External recognition further reinforces the company’s sustainability performance. In its most recent EcoVadis assessment, Samsung Biologics achieved a Platinum rating, placing it among the top one percent of companies evaluated worldwide for sustainability management practices. EcoVadis reviews environmental impact, labor and human rights standards, ethics, and sustainable procurement, providing a comprehensive benchmark of corporate responsibility. Attaining the highest rating indicates that Samsung Biologics’ environmental governance, risk management, and transparency mechanisms are operating at a leading global level.
For clients operating in increasingly sustainability-driven markets, partnerships with environmentally responsible manufacturers are becoming a competitive necessity rather than a reputational preference. Pharmaceutical companies face growing scrutiny from investors, healthcare systems, and patients regarding the environmental footprint of medicines. As a result, CDMOs that can demonstrate measurable progress and verified data are better positioned to secure long-term collaborations. Samsung Biologics’ validated PCF system therefore carries both environmental and commercial significance, strengthening trust across its global customer base.
Looking ahead, the company is expected to continue refining its carbon measurement capabilities and expanding the scope of emissions transparency. As methodologies evolve and digital technologies enhance real-time monitoring, product-level carbon data may become an integral component of pharmaceutical lifecycle management. Samsung Biologics’ early adoption of standardized, independently verified PCF calculations places it in a favorable position to adapt to these future expectations while contributing to industry-wide harmonization of sustainability reporting.
Ultimately, the independent validation of Samsung Biologics’ product carbon footprint system represents more than a technical certification. It signals a broader strategic direction centered on transparency, accountability, and collaboration in addressing climate challenges within the biopharmaceutical sector. By aligning with global standards, engaging credible third-party assurance, and integrating sustainability into core manufacturing operations, Samsung Biologics is reinforcing its role not only as a leading CDMO but also as a responsible participant in the global healthcare ecosystem.
As environmental considerations continue to shape innovation, investment, and regulation across life sciences, initiatives such as validated PCF systems are likely to become foundational rather than optional. Samsung Biologics’ latest milestone illustrates how manufacturers can combine scientific rigor, operational excellence, and sustainability leadership to meet the evolving expectations of a low-carbon future—while continuing to deliver high-quality biologic medicines to patients worldwide.
Source Link:https://samsungbiologics.com/
